Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Casi Phrmactcls Inc (CASI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
CASI Pharmaceuticals Provides Update On EVOMELA®

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, announces...

CASI : 6.46 (-3.87%)
CASI Pharmaceuticals Provides Update On EVOMELA®

ROCKVILLE, Md. , April 5, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and...

CASI : 6.46 (-3.87%)
CASI Pharmaceuticals To Present At The H.C. Wainwright Global Life Sciences Conference

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, announces...

CASI : 6.46 (-3.87%)
CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, today...

CASI : 6.46 (-3.87%)
Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and CASI Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / March 21, 2018 / Stock markets rallied Tuesday on gains from the energy and consumer discretionary sector. Wall Street appears to be eagerly awaiting details from the Federal...

CME : 161.08 (-0.32%)
ARNA : 40.38 (+0.92%)
CASI : 6.46 (-3.87%)
CASI Pharmaceuticals Announces $50 Million Private Placement To Prepare Company For Commercialization In China

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, announces...

CASI : 6.46 (-3.87%)
Factors of Influence in 2018, Key Indicators and Opportunity within Cypress Semiconductor, Abaxis,Inc, Universal Health Services, CASI Pharmaceuticals, Energy Transfer Partners, and Arconic -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cypress Semiconductor Corporation...

ETP : 18.20 (+1.11%)
UHS : 122.04 (+1.27%)
CY : 15.95 (+0.57%)
ABAX : 70.86 (-2.18%)
ARNC : 22.15 (+0.77%)
CASI : 6.46 (-3.87%)
CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference

ROCKVILLE, Md. , Feb. 9, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and...

CASI : 6.46 (-3.87%)
CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, announces...

CASI : 6.46 (-3.87%)
Wired News - CASI Pharma Purchased abbreviated new drug applications Portfolio from Sandoz

LONDON, UK / ACCESSWIRE / January 30, 2018 / Active-Investors.com has just released a free research report on CASI Pharmaceuticals, Inc. (NASDAQ: CASI). If you want access to this report all you need to...

CASI : 6.46 (-3.87%)
CASI Pharmaceuticals Acquires ANDA Portfolio From Sandoz Inc. (Sandoz)

ROCKVILLE, Md. , Jan. 26, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing quality pharmaceutical products to the Chinese and U.S....

CASI : 6.46 (-3.87%)
Free Research Reports on these Biotech Stocks -- Vericel, ZIOPHARM Oncology, Cerecor, and CASI Pharma

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on VCEL, ZIOP, CERC, and CASI which is a click away at http://www.wallstequities.com/registration....

ZIOP : 4.32 (+1.17%)
CASI : 6.46 (-3.87%)
VCEL : 11.95 (-0.83%)
CERC : 4.27 (-4.90%)
CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer SymposiumTM (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs announces a poster presentation on ENMD-2076...

CASI : 6.46 (-3.87%)
Global Biotechnology Market Showing Potential for Further Growth

According to a report by Global Market Insights, Inc., the Biotechnology Market size will exceed USD 775.2 billion with 9.9% CAGR from 2016 to 2024. Based on technology, the industry is segmented into...

ADMP : 3.65 (+2.82%)
COSM : 5.3000 (+4.33%)
INFI : 2.16 (-1.82%)
CASI : 6.46 (-3.87%)
PLX : 0.43 (unch)
CASI Pharmaceuticals Reports Third Quarter 2017 Financial Results

ROCKVILLE, Md. , Nov. 14, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (the "Company") (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization...

CASI : 6.46 (-3.87%)
CASI Pharmaceuticals Reports Third Quarter 2017 Financial Results

CASI Pharmaceuticals, Inc. (the "Company") (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other...

CASI : 6.46 (-3.87%)
Cancer Immunotherapy Technology Projected to Create Further Growth

According to data provided by Allied Market Research, the global cancer immunotherapy market is expected to grow to $117.14 billion by 2022, growing at a CAGR of 14.5 percent from the time period of 2016...

CLDX : 0.75 (+5.63%)
ARQL : 2.81 (+4.07%)
RGBP : 0.0310 (+0.32%)
RGBPP : 0.0350 (unch)
ECYT : 9.03 (+0.56%)
CASI : 6.46 (-3.87%)
Analysis: Positioning to Benefit within Tandem Diabetes Care, CASI Pharmaceuticals, SAExploration, Roka Bioscience, VirnetX, and PhaseRx - Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tandem Diabetes Care, Inc....

VHC : 2.70 (unch)
TNDM : 7.23 (+1.97%)
ROKA : 0.65 (-2.99%)
PZRX : 0.28 (-9.68%)
SAEX : 1.40 (-10.26%)
CASI : 6.46 (-3.87%)
CASI Pharmaceuticals, Capital Raise, Analysts Review, Product Development, and Guidance

NEW YORK, NY / ACCESSWIRE / October 31, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

CASI : 6.46 (-3.87%)
CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing Shareholders

ROCKVILLE, Md. , Oct. 13, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (the "Company") (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization...

CASI : 6.46 (-3.87%)

Van Meerten Stock Picks

5 Great Mid Caps
This morning I wanted to find the Mid Cap stocks that not only had some of the best returns in the past 12 months but still seemed to have some upside potential.
IBKR -0.76 , HFC -0.76 , ABMD +2.27 , CAR +0.46 , URBN +0.92
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures ended the Wednesday session with most contracts 5 to 6 cents higher, following wheat. Wednesday’s weekly EIA report showed ethanol production for the week that ended 4/20 dropping 24,000 barrels per day to 985,000 bpd. That is the ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar